Session » Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)
- 3:30PM-3:45PM
-
Abstract Number: 1458
Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study
- 3:45PM-4:00PM
-
Abstract Number: 1459
Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials
- 4:00PM-4:15PM
-
Abstract Number: 1460
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
- 4:15PM-4:30PM
-
Abstract Number: 1461
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
- 4:30PM-4:45PM
-
Abstract Number: 1462
Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares
- 4:45PM-5:00PM
-
Abstract Number: 1463
Use of Telemedicine for Follow-up of Lupus Nephritis in the COVID-19 Outbreak: The 6-month Results of a Randomized Controlled Trial